Vortioxetine (Trintellix)

Vortioxetine — Trintellix — is the SSRI that isn't quite an SSRI. The mechanism is more complex than reuptake inhibition alone, and the marketed name for that complexity is "multimodal." Whether the multimodality translates into clinically meaningful advantages over standard SSRIs is debated, but for specific patients vortioxetine has a place worth understanding.

The pharmacology is intricate. Vortioxetine inhibits SERT, like all SSRIs. It also acts as a partial agonist at 5-HT1A receptors, a partial agonist at 5-HT1B, and an antagonist at 5-HT3, 5-HT7, and 5-HT1D. Different subtypes of serotonin receptors are activated, modulated, or blocked, producing a profile that is harder to summarize than "SSRI" but conceptually closer to vortioxetine targeting the serotonin system rather than just amplifying it.

Two clinical claims distinguish vortioxetine from standard SSRIs. The first is the cognitive claim: trial data suggest vortioxetine may improve cognitive symptoms of depression — attention, processing speed, executive function — beyond what is explained by mood improvement alone. The proposed mechanism is the 5-HT7 antagonism, which has cognitive effects in animal models. The clinical signal is real but modest, and it does not appear in every trial. For the patient whose depression is dominated by cognitive complaints — "I can't concentrate, I'm slower at work, I can't read books anymore" — vortioxetine is a reasonable choice.

The second claim is the sexual dysfunction one. Vortioxetine produces lower rates of sexual dysfunction than standard SSRIs, probably through a combination of 5-HT3 antagonism and the modulatory rather than purely amplifying serotonin effect. It is not zero — the patient who experienced sexual dysfunction on sertraline may experience some on vortioxetine — but the rate is meaningfully lower. For the patient who needs a serotonergic antidepressant but found SSRI sexual side effects intolerable, vortioxetine is on the list along with bupropion augmentation and SNRI alternatives.

Side effects are typically SSRI-class. Nausea is the most common, particularly in the first week or two — usually transient. Constipation and dry mouth occur. The dose-dependent side effect pattern is similar to other SSRIs.

Dosing: start 5 to 10 milligrams daily, target 10 to 20. Once-daily, with a half-life of about 66 hours, which produces smooth steady-state and modest discontinuation effects.

The constraint is cost. Vortioxetine is brand-only and expensive. For most patients with major depression, an SSRI generic is the first move; vortioxetine becomes a thoughtful choice when cognitive symptoms are prominent, when SSRI sexual dysfunction was the limiting factor, or when standard agents have not worked. For uncomplicated depression in a cost-sensitive patient, escitalopram or sertraline does most of the same work for a fraction of the cost.

Vortioxetine is a refinement, not a revolution. For the right patient, the refinement matters.